Montelukast Heumann (Montelukast Sodium)

The drug blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from binding. This inhibition reduces bronchoconstriction, mucus production, and inflammatory cell recruitment in the airways, leading to improved breathing and fewer allergy‑related symptoms.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s age, severity of disease, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Montelukast in pregnancy and lactation are limited. Healthcare providers weigh potential benefits against possible risks before prescribing it to pregnant or nursing individuals. Patients should discuss their situation with a qualified professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting bronchodilators. It is particularly useful for patients with allergic components or exercise‑related symptoms, but it does not replace rescue inhalers for acute attacks.

Store the product at room temperature, below 25 °C, in the original packaging. Keep it away from excess moisture, direct sunlight and heat sources to maintain stability and potency.

Montelukast Heumann is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with water; do not crush or chew unless the formulation specifically allows it.

Serious concerns include rare allergic reactions such as rash, angioedema, or anaphylaxis, as well as neuropsychiatric events like depression, suicidal thoughts, and rare skin disorders such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if these occur.

Montelukast is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. It should also be avoided in patients who require immediate relief of bronchospasm, as it is not a rescue medication.